AR043120A1 - Acidos grasos de longitud de cadena mediana, gliceridos y analogos como estimuladores de la produccion de progenitores de eritrocitos - Google Patents

Acidos grasos de longitud de cadena mediana, gliceridos y analogos como estimuladores de la produccion de progenitores de eritrocitos

Info

Publication number
AR043120A1
AR043120A1 ARP040100385A ARP040100385A AR043120A1 AR 043120 A1 AR043120 A1 AR 043120A1 AR P040100385 A ARP040100385 A AR P040100385A AR P040100385 A ARP040100385 A AR P040100385A AR 043120 A1 AR043120 A1 AR 043120A1
Authority
AR
Argentina
Prior art keywords
compounds described
formula
compounds
stimulators
glycerides
Prior art date
Application number
ARP040100385A
Other languages
English (en)
Spanish (es)
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of AR043120A1 publication Critical patent/AR043120A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP040100385A 2003-02-07 2004-02-06 Acidos grasos de longitud de cadena mediana, gliceridos y analogos como estimuladores de la produccion de progenitores de eritrocitos AR043120A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44545403P 2003-02-07 2003-02-07

Publications (1)

Publication Number Publication Date
AR043120A1 true AR043120A1 (es) 2005-07-20

Family

ID=32850990

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100385A AR043120A1 (es) 2003-02-07 2004-02-06 Acidos grasos de longitud de cadena mediana, gliceridos y analogos como estimuladores de la produccion de progenitores de eritrocitos

Country Status (28)

Country Link
US (1) US9682054B2 (https=)
EP (1) EP1592416B1 (https=)
JP (1) JP5390070B2 (https=)
KR (1) KR101120775B1 (https=)
CN (1) CN100427081C (https=)
AP (1) AP2005003367A0 (https=)
AR (1) AR043120A1 (https=)
AT (1) ATE419846T1 (https=)
AU (1) AU2004210193B2 (https=)
BR (1) BRPI0407276A (https=)
CA (1) CA2515160C (https=)
CY (1) CY1108963T1 (https=)
DE (2) DE04708802T1 (https=)
DK (1) DK1592416T3 (https=)
EA (1) EA009939B1 (https=)
ES (1) ES2255467T3 (https=)
IL (1) IL170057A (https=)
JO (1) JO2705B1 (https=)
MA (1) MA27664A1 (https=)
MX (1) MXPA05008382A (https=)
MY (1) MY140913A (https=)
NO (1) NO334085B1 (https=)
NZ (1) NZ541593A (https=)
PT (1) PT1592416E (https=)
SI (1) SI1592416T1 (https=)
TN (1) TNSN05189A1 (https=)
WO (1) WO2004069237A1 (https=)
ZA (1) ZA200506246B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5026655B2 (ja) 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
CA2563533C (en) * 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII受容体ポリペプチド、方法、および組成物
MX2007002727A (es) * 2004-09-03 2008-03-04 Prometic Biosciences Inc Derivados de purinilo sustituidos con actividad inmunomoduladora y quimioprotectora, y su uso solos o con acidos grasos de longitud de cadena media o gliceridos.
NZ554176A (en) * 2004-10-01 2010-04-30 Prometic Biosciences Inc Medium-chain length fatty alcohols as stimulators of hematopoiesis
US8071580B2 (en) * 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
ES2649983T3 (es) 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EA018221B1 (ru) 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
PT2299998T (pt) * 2007-11-02 2018-04-02 Prometic Pharma Smt Ltd Acidos gordos e glicerídeos de cadeia média como agentes nefroprotetores
CN101903028B (zh) * 2007-12-19 2013-06-05 普罗米蒂克生物科学公司 与吉西他滨组合用于治疗胰腺癌的中等链长脂肪酸、盐类及三酸甘油酯
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
KR20180026795A (ko) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 절두된 ActRIIB-FC 융합 단백질
AU2010282361B2 (en) * 2009-08-13 2015-03-19 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Smt有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
CN102973922B (zh) * 2012-12-18 2016-02-03 华东理工大学 一种融合蛋白的应用
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ActRIIアンタゴニスト及び貧血を治療するための使用
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
US20170021029A1 (en) * 2015-04-15 2017-01-26 Jeffrey Charles Raber Topical formulations and uses
SG11202103011YA (en) 2018-10-11 2021-04-29 Basf As Aromatic compounds and pharmaceutical uses thereof
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871768A (en) * 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US7307166B1 (en) * 1987-10-28 2007-12-11 Wellstat Therapeutics Corporation Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis
US5011852A (en) * 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JP3014119B2 (ja) * 1990-05-28 2000-02-28 雪印乳業株式会社 直腸投与用赤血球造血剤
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
ATE147976T1 (de) * 1991-01-15 1997-02-15 Hemosphere Inc Protein nanomatrizen und verfahren zur herstellung
JPH05163160A (ja) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5214035A (en) * 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
WO1995030413A1 (en) * 1994-05-10 1995-11-16 The Kitasato Institute Hematopoietic stem cell proliferation accelerator
US5470861A (en) * 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) * 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
JPH08208510A (ja) 1994-11-03 1996-08-13 F Hoffmann La Roche Ag インターフェロン組成物
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
AUPN933396A0 (en) * 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (ja) 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
WO1999011242A1 (en) * 1997-09-04 1999-03-11 Biozone Laboratories, Inc. Oral liposomal delivery system
AU752802C (en) * 1997-11-14 2006-04-13 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
EP1032358B1 (en) * 1997-11-19 2005-05-18 Hercules Incorporated Fluidized polymer suspensions of cationic polysaccharides in emollients and use thereof in preparing personal care compositions
WO1999026640A1 (en) * 1997-11-20 1999-06-03 Bukwang Pharm. Ind. Co., Ltd. Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes
DE69825137T2 (de) * 1998-02-23 2005-07-21 Cilag Ag International Liposomale Erythropoietin-Dispersion
US6326360B1 (en) * 1998-03-11 2001-12-04 Grelan Pharmaceuticals Co., Ltd. Bubbling enteric coated preparations
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
WO2001022937A1 (en) * 1999-09-27 2001-04-05 Sonus Pharmaceuticals, Inc. Compositions of tocol-soluble therapeutics
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
AU2001264079A1 (en) 2000-06-14 2001-12-24 William Leslie Porter Lipids for modulating immune response
US6967028B2 (en) 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
JP5026655B2 (ja) * 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
US20040052836A1 (en) * 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
US6725510B1 (en) * 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
PT1648851E (pt) 2003-07-25 2007-05-31 Prometic Biosciences Inc Praparação de sais metálicos de ácidos gordos de cadeia média
MX2007002727A (es) * 2004-09-03 2008-03-04 Prometic Biosciences Inc Derivados de purinilo sustituidos con actividad inmunomoduladora y quimioprotectora, y su uso solos o con acidos grasos de longitud de cadena media o gliceridos.
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Also Published As

Publication number Publication date
EA009939B1 (ru) 2008-04-28
SI1592416T1 (sl) 2009-06-30
KR101120775B1 (ko) 2012-04-18
DE602004018902D1 (de) 2009-02-26
ES2255467T3 (es) 2009-05-01
JP5390070B2 (ja) 2014-01-15
MY140913A (en) 2010-01-29
PT1592416E (pt) 2009-04-03
CA2515160C (en) 2013-01-08
CN100427081C (zh) 2008-10-22
JP2006516987A (ja) 2006-07-13
NO20053994L (no) 2005-10-06
EP1592416B1 (en) 2009-01-07
KR20050118671A (ko) 2005-12-19
US20060128800A1 (en) 2006-06-15
EA200501267A1 (ru) 2006-02-24
CA2515160A1 (en) 2004-08-19
US9682054B2 (en) 2017-06-20
DE04708802T1 (de) 2006-06-22
MXPA05008382A (es) 2005-11-04
AU2004210193B2 (en) 2007-07-12
NZ541593A (en) 2009-05-31
MA27664A1 (fr) 2005-12-01
JO2705B1 (ar) 2014-03-15
ZA200506246B (en) 2006-12-27
AU2004210193A1 (en) 2004-08-19
BRPI0407276A (pt) 2006-01-31
CN1753665A (zh) 2006-03-29
ES2255467T1 (es) 2006-07-01
CY1108963T1 (el) 2014-07-02
NO334085B1 (no) 2013-12-09
WO2004069237A1 (en) 2004-08-19
NO20053994D0 (no) 2005-08-26
TNSN05189A1 (en) 2007-06-11
AP2005003367A0 (en) 2005-09-30
ATE419846T1 (de) 2009-01-15
IL170057A (en) 2011-09-27
DK1592416T3 (da) 2009-04-20
EP1592416A1 (en) 2005-11-09

Similar Documents

Publication Publication Date Title
AR043120A1 (es) Acidos grasos de longitud de cadena mediana, gliceridos y analogos como estimuladores de la produccion de progenitores de eritrocitos
RU2144356C1 (ru) Композиция для инъекций на основе таксоидов
Jodko-Piórecka et al. Antioxidant activity of dopamine and L-DOPA in lipid micelles and their cooperation with an analogue of α-tocopherol
ES2248272T5 (es) Formulación de fulvestrant
FI68173B (fi) Foerfarande foer framstaellning av lokalanestesiskt verksamma kombinationspreparat
ES2063011T3 (es) Agentes antibacteriales de quinolonas y naftiridinas que contienen un alfa-aminoacido en la cadena lateral del 7-sustituyente.
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
GEP20002069B (en) Taxoid Based Pharmaceutical Compositions and Method for its Production
ECSP034563A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos
RU2008141682A (ru) Лечение раковых заболеваний при помощи комбинации таксанов и 13-дезоксиантрациклинов
AR041932A1 (es) Derivados de ciclohexano espirociclicos, preparacion de los mismos, su uso en la fabricacion de medicamentos y dichos medicamentos.
MX2008012844A (es) Composiciones farmaceuticas y usos de ellas.
AR026122A1 (es) Derivados de 3(5)-amino-pirazol, procedimiento para su preparacion y su uso como agente antitumorales
JP6052929B2 (ja) 乳酸エステルをベースとするフルベストラント又はその誘導体の油性製剤およびその製造方法
AR030007A1 (es) Compuesto de ciclohexilo, su uso para la manufactura de un medicamento, agente de diagnostico, composicion farmaceutica que lo contiene, proceso para su preparacion, compuestos para su exclusivo uso en la preparacion de dichos compuestos de ciclohexilo, y metodo de tratamiento
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
ES2848559T3 (es) Microesferas que contienen lactonas macrocíclicas antihelmínticas
CO5380014A1 (es) Formulacion farmaceuticas para la administracion oral o topica de compuestos hidrofobicos que no frma emulsion
ES2132101T3 (es) Procedimiento para la preparacion de un medicamento destinado a la administracion por via oral o topica en el tratamiento de leishmaniasis.
MX9604092A (es) Composiciones estables, opticamente claras.
AR046874A1 (es) Nuevos metodos
EA200401565A1 (ru) Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
HRP20030907B1 (hr) Farmaceutska kompozicija na bazi makrolida za lokalnu upotrebu u oftalmologiji
RU2010104872A (ru) Гидрогель карбоксиалкиламида хитозана, его приготовление и применение в косметологии и дерматологии
FR2393577A1 (fr) Medicament a base d'acide b-(p-halogenophenyl)-g-aminobutyrique destine au traitement de la nevrose d'angoisse

Legal Events

Date Code Title Description
FA Abandonment or withdrawal